Royal Bank of Canada
RNAZ icon

Royal Bank of Canada’s TransCode Therapeutics RNAZ Stock Holding History

Royal Bank of Canada’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
8
– – ﹤0.01% 7607
2025
Q4 		$0 Hold
8
– – ﹤0.01% 7564
2025
Q3 		$0 Hold
8
– – ﹤0.01% 7468
2025
Q2 		$0 Sell
8
-1
-11% -$9 ﹤0.01% 7300
2025
Q1 		$0 Buy
+9
New +$1.15K ﹤0.01% 7182
2024
Q3 		– Hold
0
– – – 7348
2024
Q2 		– Hold
0
– – – 7460
2024
Q1 		– Hold
0
– – – 7507
2023
Q4 		– Hold
0
– – – 7510
2023
Q3 		– Hold
0
– – – 7499
2023
Q2 		– Hold
0
– – – 7602
2022
Q4 		– Hold
0
– – – 7638
2022
Q3 		– Hold
0
– – – 7785
2022
Q1 		– Hold
0
– – – 7969
2021
Q4 		– Hold
0
– – – 7854

Other funds holding RNAZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Royal Bank of Canada's RNAZ Position: Q1 2026 in Review

Royal Bank of Canada held its TransCode Therapeutics (RNAZ) position steady in Q1 2026 at 8 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7607.

Royal Bank of Canada first reported a position in RNAZ in Q1 2025 and has held it in 5 quarters since. 8 funds tracked by Wall St. Rank hold RNAZ as of Q1 2026.

  • Royal Bank of Canada held 8 shares of TransCode Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada left its TransCode Therapeutics share count unchanged in Q1 2026.
  • TransCode Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7607 holding.
  • Royal Bank of Canada first reported a position in TransCode Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.